29 results on '"Inzucchi, Silvio E."'
Search Results
2. Dapagliflozin in patients with heart failure and previous myocardial infarction: A participant‐level pooled analysis of DAPA‐HF and DELIVER
3. Impact of COVID‐19 in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction Enrolled in the DELIVER Trial
4. Heart failure, chronic obstructive pulmonary disease and efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: Insights from DELIVER
5. Renal and blood pressure effects of dapagliflozin in recently hospitalized patients with heart failure with mildly reduced or preserved ejection fraction: Insights from the DELIVER trial
6. Effect of dapagliflozin on health status and quality of life across the spectrum of ejection fraction: Participant‐level pooled analysis from the DAPA‐HF and DELIVER trials
7. Effects of Dapagliflozin on Heart Failure Hospitalizations According to Severity of Inpatient Course: Insights from DELIVER and DAPA‐HF
8. Effects of Dapagliflozin on Heart Failure Hospitalizations According to Severity of Inpatient Course: Insights from <scp>DELIVER</scp> and <scp>DAPA‐HF</scp>
9. Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan
10. Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial
11. Liver tests and outcomes in heart failure with reduced ejection fraction: findings from DAPA‐HF
12. Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA‐HF
13. Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes
14. Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA‐HF
15. Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index
16. Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of theDELIVERtrial
17. Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA‐HF trial
18. Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA‐HF.
19. Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA‐HF
20. Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA‐REG OUTCOME trial
21. Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA-REG OUTCOME trial.
22. Effect of dapagliflozin on anaemia in DAPA‐HF.
23. A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF).
24. Efficacy and safety of sodium-glucose co-transporter 2 inhibition according to left ventricular ejection fraction in DAPA-HF.
25. Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trial.
26. The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics.
27. Heart failure outcomes in clinical trials of glucose‐lowering agents in patients with diabetes
28. Effects of dapagliflozin according to QRS duration across the spectrum of left ventricular ejection fraction: An analysis of DAPA‐HF and DELIVER.
29. Dapagliflozin and quality of life measured using the EuroQol 5‐dimension questionnaire in patients with heart failure with reduced and mildly reduced/preserved ejection fraction.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.